Clinical Trials Logo

mCRPC clinical trials

View clinical trials related to mCRPC.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01818986 Completed - mCRPC Clinical Trials

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Start date: July 10, 2013
Phase: Phase 2
Study type: Interventional

In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically to the concurrently administered immunotherapy Sipuleucel-T and thereby significantly improve the treatment outcome for metastatic castrate resistant prostate cancer patients (mCRPC). Both Sipuleucel-T and SABR are FDA approved therapeutic cancer treatment